Comorbidities in patients with uterine adenosarcoma. A single-center case series of 12 patients

Abstract

Abstract Background: Uterine adenosarcoma is a rare low-grade tumor that commonly affects elderly women and is associated with a generally good, although sometimes poor, prognosis. This study investigates the effect of comorbidities in old patients with uterine adenosarcoma. Methods: A review of patients who had been diagnosed with uterine adenosarcoma at our institution between 2010 and 2020 was conducted. All patients underwent a specialist pathological reviewand were re-staged according to the International Federation of Gynecology and Obstetrics 2009 criteria. Patient demographics, staging, histologic features, primary and adjuvant therapy, disease recurrence, and survival time were collected. Results: Twelve patients with confirmed uterine adenosarcomas were identified. Their mean age at diagnosis was 58.3 years (range, 31–83 years). Eight patients had pre-existing chronic diseases at the time of diagnosis. All 12 patients underwent surgical therapy. Of these, 10 (83.3%) were stage I, 1 (8.3%) was stage II, and 1 (8.3%) was stage III. Postoperative adjuvant therapies included chemotherapy (n = 1), radiation (n = 1), or no further therapy (n = 10). The mean follow-up duration was 39.2 months (range, 7–104 months). The recurrence and mortality rates were 16.7% (2/12) and 41.7% (5/12), respectively. Five recurrence-free patients died of comorbidities. The mean postoperative survival of these 5 patients was 22.6 months. The remaining seven patients were free of recurrence at the time of this report. Conclusions: Comorbidities with age is a significant factor leading to poor prognosis in uterine adenosarcomas. Greater attention should be paid to elderly patients with comorbidities. Targeted interventions, including multi-professional management, tailored assessment, and follow-up, may contribute to improved well-being.